Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (original) (raw)

• Jain, R.K. The next frontier of molecular medicine: delivery of therapeutics. Nature Med. 4, 655–657 (1998).
  Article CAS Google Scholar
• Browder, T. et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug–resistant cancer. Cancer Res. 60, 1878–1886 (2000).
  CAS PubMed Google Scholar
• Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–24 (2000).
  Article CAS Google Scholar
• Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
  Google Scholar
• Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
  Article CAS Google Scholar
• Teicher, B.A. A systems approach to cancer therapy. Cancer Metastasis Rev. 15, 247–272 (1996).
  Article CAS Google Scholar
• Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
  CAS PubMed Google Scholar
• Jain, R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58–65 (1994).
  Article CAS Google Scholar
• Baish, J. et al. Fractals and cancer. Cancer Res. 60, 3683–3688 (2000).
  CAS PubMed Google Scholar
• Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
  CAS PubMed Google Scholar
• Yuan F., et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-VEGF/VPF antibody. Proc. Natl. Acad. Sci. USA 93, 14765–14770 (1996).
  Article CAS Google Scholar
• Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
  CAS PubMed Google Scholar
• Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
  CAS PubMed Google Scholar
• Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
  CAS PubMed Google Scholar
• Jain, R.K. et al. Endothelial cell death, angiogenesis, and microvascular function following castration in an androgen-dependent tumor: Role of VEGF. Proc. Natl. Acad. Sci. USA 95, 10820–10825 (1998).
  Article CAS Google Scholar
• Uehara, H., Kim, S.J., Karashima, T., Zheng, L. & Fidler, I.J. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice. Abstract 2192. American Association for Cancer Research 92nd Annual Meeting, New Orleans (April 2001).
• Viloria-Petit, A. et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61, 5090–5101 (2001).
  CAS PubMed Google Scholar
• Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).
  Article CAS Google Scholar
• Fidler, I.J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. 93, 1040–1041 (2001).
  Article CAS Google Scholar
• Ruoslahti, E. Targeting tumor vasculature with homing peptides from phage display. Semin. Cancer Biol. 10, 435–442 (2000).
  Article CAS Google Scholar
• Thorpe, P.E. & Ran, S. Tumor infarction by targeting tissue factor to tumor vasculature. Cancer J. Sci. Am. 6 Suppl 3, S237–244 (2000).
  Google Scholar
• Gasparini, G. et al. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 4, 2625–2634 (1998).
  CAS PubMed Google Scholar
• St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197–1202 (2000).
  Article CAS Google Scholar
• Griffon-Etienne, G. et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59, 3776–3782 (1999).
  CAS PubMed Google Scholar
• Murata, R., Nishimura, Y. & Hiraoka, M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37, 1107–1113 (1997).
  Article CAS Google Scholar
• Ma, J. et al. Pharmacodynamic-mediated reduction of Temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61, 5491–5498 (2001).
  CAS PubMed Google Scholar
• Gullino, P.M. Angiogenesis and oncogenesis. J. Natl. Cancer Inst. 61, 639–643 (1978).
  CAS PubMed Google Scholar
• Milosevic, M. et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 61, 6400–6405 (2001).
  CAS PubMed Google Scholar